Dr. Fisher Farma B.V. Sustainability Profile
Dr. Fisher Farma B.V., headquartered in the Netherlands, is a prominent player in the pharmaceutical industry, specialising in the development and distribution of high-quality medicinal products. Founded in 2005, the company has established a strong presence across Europe, focusing on innovative solutions in the fields of oncology, cardiology, and neurology. With a commitment to excellence, Dr. Fisher Farma offers a diverse range of pharmaceuticals that are distinguished by their efficacy and safety profiles. The company’s dedication to research and development has led to several key milestones, including the successful launch of multiple proprietary formulations. Recognised for its robust market position, Dr. Fisher Farma continues to expand its operational footprint, striving to enhance patient outcomes through advanced therapeutic options.
DitchCarbon Score
How does Dr. Fisher Farma B.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dr. Fisher Farma B.V.'s score of 23 is lower than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dr. Fisher Farma B.V.'s reported carbon emissions
Dr. Fisher Farma B.V., headquartered in the Netherlands (NL), currently does not have specific carbon emissions data available, as indicated by the absence of reported figures. The company is classified as a current subsidiary and does not inherit emissions data from a parent organisation. Consequently, there are no documented reduction targets or climate pledges at this time. As a current subsidiary, Dr. Fisher Farma B.V. may be expected to align with broader industry standards and practices regarding climate commitments, although specific initiatives or targets have not been disclosed. The absence of emissions data and reduction initiatives suggests that the company may still be in the early stages of developing its climate strategy. In the context of the pharmaceutical industry, companies are increasingly focusing on sustainability and carbon reduction, often setting science-based targets to mitigate their environmental impact. However, without specific commitments or data, it is unclear how Dr. Fisher Farma B.V. plans to address its carbon footprint moving forward.
How Carbon Intensive is Dr. Fisher Farma B.V.'s Industry?
How Carbon Intensive is Dr. Fisher Farma B.V.'s Location?
Dr. Fisher Farma B.V.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Dr. Fisher Farma B.V. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Orifarm
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.